C5 Inhibitor Antibodies for Complement-Associated Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The complement system, while essential for defending against pathogens, can lead to inappropriate regulation and activation, contributing to various disorders such as rheumatoid arthritis, lupus nephritis, and ischemia-reperfusion injury, where existing treatments are often ineffective in managing these conditions.
Innovation Solution
Compositions containing inhibitors of human complement component C5, such as antibodies or small molecules, are administered to prevent or treat complement-associated disorders by inhibiting the complement system's inappropriate activation, specifically targeting C5 or its fragments C5a and C5b to reduce inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the complement system is activated to defend against pathogens, then immune defense function is improved, but inappropriate activation leads to complement-associated disorders such as rheumatoid arthritis, lupus nephritis, and ischemia-reperfusion injury
Solution Approach 1:
The patent uses C5 inhibitor antibodies as intermediary substances that specifically bind to complement component C5, blocking its activation and preventing the formation of C5a and C5b fragments. This intermediary approach selectively inhibits the harmful complement cascade while preserving other immune defense mechanisms that do not depend on C5 activation.
Solution Approach 2:
The patent changes the activation state parameter of the complement system by introducing C5 inhibitors that prevent the conformational change and activation of C5. This parameter change selectively suppresses the complement cascade pathway responsible for tissue damage while maintaining the system's ability to respond to pathogens through other pathways.
2Ease of manufacture
If existing treatments are used for complement-associated disorders, then general management is provided, but treatments are often ineffective in managing these conditions
Solution Approach 1:
The patent extracts and specifically targets the C5 component from the complex complement system, isolating the critical point of no return in the complement cascade. By developing inhibitors that specifically bind to C5, the treatment addresses the root cause of complement-mediated tissue damage rather than providing general symptomatic management with conventional therapies.
Solution Approach 2:
The C5 inhibitor antibodies serve as specific intermediary agents that bridge the gap between the complement system and therapeutic intervention. These antibodies selectively interfere with C5 activation, providing a targeted mechanism of action that conventional non-specific anti-inflammatory treatments cannot achieve.
3Reliability
If C5 inhibitors are administered to inhibit complement activation, then systemic complement activity is reduced and symptoms are alleviated, but chronic administration is required to maintain inhibition and prevent irreversible damage
Solution Approach 1:
The patent implements continuous therapeutic action through chronic administration of C5 inhibitors, maintaining sustained suppression of complement activation. This continuous intervention prevents the complement system from recovering and causing irreversible tissue damage, ensuring long-term protection against complement-associated disorders through ongoing inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of C5 inhibitors effectively treats or prevents complement-associated disorders by reducing systemic complement activity, alleviating symptoms like hypertension and proteinuria, and potentially reducing the need for plasma therapy, with chronic administration maintaining systemic inhibition and preventing irreversible damage.
Implementation Method 1
compositions containing an inhibitor of human complement (e.g., an inhibitor of complement component C5 such as an anti-C5 antibody)
Data Source
AI summary
The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.